scienceneutral
FRCs and Gelatin: A New Hope for Diabetes Treatment
Friday, June 6, 2025
But how do these scaffolds work in living organisms? Scientists tested them in mice. They found that the scaffolds allowed FRCs to survive for at least 21 days. However, the results varied depending on the type of mouse and where the scaffolds were implanted. This highlights the complexity of the immune system and the challenges of developing new treatments.
The scaffolds also showed promise in modulating T cells, which are key players in the immune response. When T cells were co-cultured with FRCs presenting T1D antigens, the T cells showed reduced cytotoxic activity. This means they were less likely to attack healthy cells. Instead, they showed increased anergic and regulatory phenotypes. This is a good sign. It suggests that these scaffolds could help in developing treatments that specifically target the immune response in T1D.
In summary, these gelatin scaffolds offer a new way to study and potentially treat T1D. They support FRC growth and function, survive in living organisms, and modulate T cell activity. However, more research is needed to fully understand their potential and overcome the challenges they present.
Actions
flag content